21 results on '"Batteson, R"'
Search Results
2. EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METEX14) Skipping
3. CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14) Skipping Non-Small Cell Lung Cancer (NSCLC)
4. CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)
5. EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping
6. PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping
7. CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14) Skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC
8. RWD51 Demonstrating Internal and External Validity in Real-World Datasets: A Case Study in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)
9. EE146 Cost-effectiveness of Tepotinib for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring Metex14 Skipping Alterations in Spain
10. PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK
11. PRM23 - MODELLING CANCER TREATMENTS IN THE ADJUVANT SETTING: A TARGETED LITERATURE REVIEW (TLR) OF TECHNOLOGY APPRAISALS (TA) OF ADJUVANT THERAPIES SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND A CASE STUDY IN ADJUVANT MELANOMA.
12. PRM21 - MODELLING SURVIVAL OF PATIENTS WITH COMPLETELY RESECTED ADVANCED MELANOMA WITH ADJUVANT TREATMENT OF NIVOLUMAB VERSUS OBSERVATION
13. Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin Versus Investigators Choice (IC) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (R/R B-ALL)
14. HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals.
15. PCN205 - Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin Versus Investigators Choice (IC) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (R/R B-ALL)
16. Chapter 5.7 : Occupational therapy and ergonomy
17. DeQuervain's disease: clinical features, precipitating factors and treatment -- a literature review.
18. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
19. Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection.
20. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
21. The de Quervain's screening tool: validity and reliability of a measure to support clinical diagnosis and management.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.